The world’s first Phase 3 psilocybin clinical trial is about to commence
New Atlas, October 25, 2022
The world’s first Phase 3 human trial for day psilocybin therapy with psychological support due to commence by the end of 2022. The trial will enroll close to 1,000 participants and Compass is looking to FDA approval by the end of 2025.
Shroom A Magic Cure
Herald Sun, October 24, 2022
Melbourne team makes anorexia breakthrough.
Professor Arthur Christopoulos speaks at Academy of Law and Academy of Science Joint Symposium
Academy of Law and Academy of Science Joint Symposium, October 18, 2022
Yesterday, Professor Arthur Christopoulos, Dean of the Faculty of Pharmacy & Pharmaceutical Sciences, and inaugural Director of the Neuromedicines Discovery Centre at Monash University, spoke at the Academy of Law and Academy of Science Joint Symposium.
He spoke of the vast divide between science and the law, in reference to the scheduling of medicines, and particularly focusing on psilocybin and MDMA. As the TGA finalises the interim decision on the rescheduling of these medicines, it would be important to keep his words in mind.
Psychedelic Medicine Is Going Beyond PTSD and Depression
Lucid News, October 13, 2022
Though psychedelic treatments for a few major indications get all the headlines, there are many more conditions that psychedelic treatments are being investigated for.
Psychedelics are Exploding in the Startup Community as Founders Say it Makes Them Better Leaders
FortuneWell, October 6, 2022
Ayahuasca’s effects may feel like “talk therapy on steroids” because the hallucinations reveal what many interpret as a deeper truth about themselves, their life, or life in general. Often called ayahuasca “teachings,” these visions may provide the type of self-awareness critical to being a good leader. Business leadership research shows that when leaders can regulate their own negative emotional responses, they can better identify their team’s needs and provide them the encouragement or motivation they need.
Kiwi trial to investigate psilocybin and treatment-resistant depression
NZ Herald, September 28, 2022
A new trial is set to look into whether psilocybin could provide effective treatment for those with severe depression.
Researchers Studying Psychedelic Drug as Treatment for Alzheimer’s Disease
High Times, September 21, 2022
A Toronto-based biotech company is studying a psychedelic drug based on DMT as a treatment for Alzheimer’s disease with a Phase ll clinical trial in Argentina.
Mushrooms for meds: Psychedelics are changing treatment ways in Israel
Y Net News, September 16, 2022
Ecstasy for PTSD and ketamine for long-term depression – is this game changer set to revolutionize mental health treatment in Israel and elsewhere?
Psilocybin Study To Investigate the Serotonin System in Autism
Technology Networks, September 7, 2022
Technology Networks spoke to Tobias Whelan, PhD student at King’s College London and research scientist at COMPASS Pathways, who is conducting the study, to learn more about this first-ever mechanistic study of psilocybin in autistic adults.
Is the Serotonin Hypothesis about Depression Wrong?
Amen Clinics, August 30, 2022
For over 30 years of clinical practice, Amen Clinics has been saying that a serotonin imbalance may be present in some people with depression, but it is not the only cause of depressive symptoms. Depression is not just one thing. Find out the seven causes of depression that aren’t related to serotonin.
Psychedelic Drugs Take On Depression
Nature Briefing, August 24, 2022
Mind-altering drugs might provide relief for those who don’t respond to conventional therapies — but does the hype outweigh the hope? What is clear is that new therapies are urgently needed. The coronavirus pandemic has left more people in mental distress than ever before. Psychedelics offer the possibility of relief for people who have no other options.
Psychedelic Drug Therapy a Breakthrough for Alcohol Dependence?
Medscape, August 24, 2022
Psilocybin paired with psychotherapy is associated with a robust and sustained decrease in drinking among adults with alcohol use disorder (AUD), new research suggests.
The long history of psychedelics in religion, from ergot-spiked wine to magic mushrooms
ABC News, August 21, 2022
In the last century, psychedelics have gone from being at the cutting edge of medical science, to a symbol of the 1960s counterculture, and back again.
The Need For 100,000 Psychedelic Facilitators Is Real
LA Weekly, August 3, 2022
The experts are pretty sure it’s going to take 100,000 psychedelic facilitators for the new industry to provide treatment to the masses.
Canadian patients fighting for psilocybin access sue federal government
National Post, August 2, 2022
‘This is the landmark case that is going to legalize psychedelics in Canada’
Restrictions on Psilocybin ‘Magic Mushrooms’ Are Easing as Research Ramps Up
Scientific American, August 1, 2022
Here’s how the psychedelic substance’s legal status has been shifting.
Biden administration plans for legal psychedelic therapies within two years
The Intercept, July 27, 2022
A letter from the Health and Human Services Department discloses the anticipated FDA approval of MDMA and psilocybin treatments.
Major health insurer opens door to psychedelic drugs
The Australian, July 26, 2022
Health insurer says psychedelics’ medicinal potential is ‘extraordinary’ amid growing evidence MDMA and psilocybin can be used to treat some mental illnesses.
Microdosing: Scientists tackle psychedelic trend becoming ‘creative enhancer of choice’
The Age, July 23, 2022
Microdosing is a different way of consuming psychedelic medicines, which involves regularly taking small amounts of a psychedelic.
Biotech Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
The Australian, July 21, 2022
In a groundbreaking development, the US FDA has just approved a clinical trial studying the effects of naturally derived psychedelic medicines.